Pharmacogenetics of Mylotarg
OBJECTIVES:
- To analyze candidate-coding polymorphisms in CD33 of DNA samples from children with
newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on
COG-AAML03P1.
- To determine the association between these polymorphisms and clinical response of
patients treated with this regimen.
OUTLINE: Archived DNA samples are analyzed for candidate polymorphisms in CD33 by PCR-based
sequencing.
Observational
N/A
Association between coding polymorphisms in CD33 with clinical response to gemtuzumab ozogamicin
No
Jatinder Lamba, MD
Principal Investigator
Masonic Cancer Center, University of Minnesota
United States: Federal Government
CDR0000671448
NCT01139320
September 2009
Name | Location |
---|